---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-057785"
form_type: "8-K"
ticker: "COGT"
cik: "0001622229"
company_name: "Cogent Biosciences, Inc."
filed_at: "2023-11-02T23:59:59+00:00"
generated_at: "2026-06-09T00:27:57.933789+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Cogent Biosciences Q3 net loss $55.4M; cash $312.8M providing runway into 2026

## Summary
- Net loss of $55.4M for Q3 2023 vs $35.1M in Q3 2022; R&D expenses $50.1M (up 67% YoY).
- Cash, cash equivalents and marketable securities $312.8M as of Sept 30, 2023, down from $350.9M at June 30, 2023.
- SUMMIT NonAdvSM trial Part 1 enrollment completed at 54 patients; Part 2 registration-directed trial to begin 1H 2024.
- APEX AdvSM trial Part 2 enrollment on track to complete by end 2024; SUMMIT Part 1a data selected for oral presentation at ASH 2023.
- PEAK Phase 3 GIST study lead-in data shows 33% ORR in 2nd-line; Phase 3 enrollment on track by end 2024.

## SEC filing metadata
- accession: 0000950170-23-057785
- form_type: 8-K
- ticker: COGT
- cik: 0001622229
- company_name: Cogent Biosciences, Inc.
- filed_at: 2023-11-02T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1622229/000095017023057785/0000950170-23-057785-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1622229/000095017023057785/cogt-20231102.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-057785
- JSON: https://secwatch.observer/filing/0000950170-23-057785.json
- Plain text: https://secwatch.observer/filing/0000950170-23-057785.txt

## Key facts
- Earnings Releases
  Cogent Biosciences, Inc. reported financial results for the third quarter ended September 30, 2023.
  - Period: the third quarter ended September 30, 2023
  - Result: reported results
  source text: On November 2, 2023, Cogent Biosciences, Inc., a Delaware corporation (the “Company”), issued a press release announcing its financial results for the quarter ended September 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1622229/000095017023057785/0000950170-23-057785-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.